Blog

Aren Karapetyan: New study on nasopharyngeal carcinoma shows improved outcomes with Nedaplatin

Photo from Aren Karapetyan/LinkedIn

Sep 27, 2024, 16:51

Aren Karapetyan: New study on nasopharyngeal carcinoma shows improved outcomes with Nedaplatin

Aren Karapetyan, Oncology Resident at Yerevan State Medical University, shared the following on LinkedIn:

“New study on nasopharyngeal carcinoma shows that fatigue and appetite loss during chemoradiotherapy significantly increase the risk of distant metastasis. Nedaplatin proved as effective as Cisplatin, with better tolerance and less toxicity.”

Joint modeling of longitudinal health-related quality of life during concurrent chemoradiotherapy period and long-term survival among patients with advanced nasopharyngeal carcinoma

Authors: Ji-Bin Li, Shan-Shan Guo, Ting Liu, Zhuo-Chen Lin, Wei-Jie Gong, Lin-Quan Tang, Ling Guo, Hao-Yuan Mo, Hai-Qiang Mai & Qiu-Yan Chen.

Source: Aren Karapetyan/LinkedIn

appetite loss Aren Karapetyan cancer chemoradiotherapy Cisplatin distant metastasis fatigue nasopharyngeal carcinoma Nedaplatin OncoDaily Oncology toxicity treatment tolerance

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage